2024-514176-41-00招募中1 期
A Phase 1b Study of JNJ-80948543 in Combination with Other CD3 TCEs for R/R B-cell NHL
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 16
- 试验地点
- 5
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
CTIS Point of Contact
Scientific
Janssen Cilag International
研究点 (5)
Loading locations...
相似试验
进行中（未招募）
1 期
A study of JNJ-75276617 in combination with acute myeloid leukemia-directed therapiesCancerAcute myeloid leukemiaISRCTN12278036Janssen Pharmaceutica NV150
招募中
1 期
A Phase 1 Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms2024-513199-16-00Janssen Cilag International20
进行中（未招募）
1 期
A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)Lymphoma, Non-HodgkinNCT06660563Janssen Research & Development, LLC19
招募中
1 期
A Phase 1b Study of JNJ-90014496 in Adult Participants with Relapsed or Refractory B-cellNon-Hodgkin Lymphomaon-Hodgkin Lymphoid MalignanciesCTIS2023-506267-33-00Janssen - Cilag International54
已完成
1 期
A Phase I/II study of JR-031 for the patients of standard primary treatment-refractory acute graft-versus-host disease (acute GVHD) after hematopoietic stem cell transplantatioStandard primary treatment-refractory acute GVHDJPRN-UMIN000001716JCR pharmaceuticals Co.,Ltd20